Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

TY - JOUR

T1 - Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

AU - Bergmann, Natasha Chidekel

AU - Lund, Asger

AU - Gasbjerg, Lærke Smidt

AU - Jørgensen, Niklas Rye

AU - Jessen, Lene

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Christensen, Mikkel Bring

AU - Vilsbøll, Tina

AU - Knop, Filip Krag

N1 - Copyright © 2019 Endocrine Society.

PY - 2019/3/21

Y1 - 2019/3/21

N2 - The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been suggested to play a role in bone metabolism. Exogenous administration of GIP inhibits bone resorption, but the effect of GLP-1 is less clear. Furthermore, the combined effect of exogenous GIP and GLP-1 on bone metabolism is unknown. Objective: To investigate the effect of separate and combined infusions of the incretin hormones GIP and GLP-1 on bone resorption and formation. Design: Randomized, double-blinded, placebo-controlled, crossover study including five study days. Participants: Seventeen overweight/obese men. Interventions: On the first study day, a 50-g oral glucose tolerance test (OGTT) was performed. On the next four study days, isoglycemic IV glucose infusions (IIGI), mimicking the glucose excursions from the OGTT, were performed with concomitant infusions of GIP (4 pmol/kg/min), GLP-1 (1 pmol/ kg/min), GIP1GLP-1 (4 and 1 pmol/kg/min, respectively), or placebo, respectively. Primary Outcomes: Changes in bone resorption assessed by measurements of carboxy-terminal type I collagen crosslinks (CTX) and in bone formation as assessed by procollagen type 1 N-terminal propeptide (P1NP) concentrations.

AB - The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been suggested to play a role in bone metabolism. Exogenous administration of GIP inhibits bone resorption, but the effect of GLP-1 is less clear. Furthermore, the combined effect of exogenous GIP and GLP-1 on bone metabolism is unknown. Objective: To investigate the effect of separate and combined infusions of the incretin hormones GIP and GLP-1 on bone resorption and formation. Design: Randomized, double-blinded, placebo-controlled, crossover study including five study days. Participants: Seventeen overweight/obese men. Interventions: On the first study day, a 50-g oral glucose tolerance test (OGTT) was performed. On the next four study days, isoglycemic IV glucose infusions (IIGI), mimicking the glucose excursions from the OGTT, were performed with concomitant infusions of GIP (4 pmol/kg/min), GLP-1 (1 pmol/ kg/min), GIP1GLP-1 (4 and 1 pmol/kg/min, respectively), or placebo, respectively. Primary Outcomes: Changes in bone resorption assessed by measurements of carboxy-terminal type I collagen crosslinks (CTX) and in bone formation as assessed by procollagen type 1 N-terminal propeptide (P1NP) concentrations.

U2 - 10.1210/jc.2019-00008

DO - 10.1210/jc.2019-00008

M3 - Journal article

C2 - 30848791

SN - 0021-972X

VL - 104

SP - 2953

EP - 2960

JO - The Journal of clinical endocrinology and metabolism

JF - The Journal of clinical endocrinology and metabolism

IS - 7

ER -